As previously announced, planning is underway with FDA to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection As anticipated, an End of Phase 2.
All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained.
In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary.
STATEN ISLAND, N.Y., Oct. 25, 2023 /PRNewswire/ Acurx Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial.
Based on observed aggregate blinded data the Company has determined that both treatments, ibezapolstat and the control antibiotic vancomycin, have performed as.